Payment overview · 2025
General Payments
$272.21
15 reported records · 8 companies
Healthcare provider profile · identity verified
Paul H Karakourtis, MD
Allopathic & Osteopathic Physicians|Family Medicine · ARLINGTON, TX · NPI 1841237104
Verified facts
What the public records show
CMS Open Payments records show Paul H Karakourtis, MD received $272.21 in general payments during 2025 across 15 reported records.
PFIZER INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $89.82 | 33.0% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.87 | 13.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.59 | 11.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.70 | 10.9% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $27.58 | 10.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $25.88 | 9.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.24 | 6.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.53 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $272.21 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.44 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.44 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.70 | 2 | 2025 |
Source payment records
|
|||||
| AMS 700 Normalized: ams 700 |
Device | Boston Scientific Corporation | $25.88 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
75 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 667 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 361 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 105 |
| Losartan Potassium | Losartan Potassium | 294 | 85 |
| Metformin Hcl | Metformin Hcl | 283 | 79 |
| Lisinopril | Lisinopril | 220 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 215 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 195 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 190 | 68 |
| Omeprazole | Omeprazole | 184 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 49 |
| Gabapentin | Gabapentin | 168 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 53 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 158 | 47 |
| Trazodone Hcl | Trazodone Hcl | 155 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 56 |
| Carvedilol | Carvedilol | 139 | 40 |
| Meloxicam | Meloxicam | 124 | 58 |
| Ozempic | Semaglutide | 124 | 26 |
| Sertraline Hcl | Sertraline Hcl | 119 | 29 |
| Metformin Hcl Er | Metformin Hcl | 116 | 36 |
| Simvastatin | Simvastatin | 111 | 32 |
| Montelukast Sodium | Montelukast Sodium | 108 | 35 |
| Clonidine Hcl | Clonidine Hcl | 94 | 38 |
| Valsartan | Valsartan | 94 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 31 |
| Glimepiride | Glimepiride | 88 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 29 |
| Amoxicillin | Amoxicillin | 80 | 70 |
| Eliquis | Apixaban | 75 | 18 |
| Ezetimibe | Ezetimibe | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Jardiance | Empagliflozin | 66 | 20 |
| Allopurinol | Allopurinol | 65 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 25 |
| Furosemide | Furosemide | 63 | 27 |
| Bupropion Xl | Bupropion Hcl | 59 | 18 |
| Prednisone | Prednisone | 59 | 41 |
| Alendronate Sodium | Alendronate Sodium | 57 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 19 |
| Buspirone Hcl | Buspirone Hcl | 53 | 14 |
| Cefdinir | Cefdinir | 53 | 43 |
| Tramadol Hcl | Tramadol Hcl | 52 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | 13 |
| Nifedipine Er | Nifedipine | 47 | 14 |
| Atenolol | Atenolol | 45 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 25 |
| Finasteride | Finasteride | 44 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 12 |
| Lovastatin | Lovastatin | 42 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 40 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 14 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 22 |
| Glipizide | Glipizide | 35 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 21 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 15 |
| Alprazolam | Alprazolam | 31 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 18 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 17 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $272.21 · 15 records | PFIZER INC. | AIRSUPRA, AMS 700, Dexcom G6 Transmitter, JARDIANCE, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error